中国全科医学

所属专题: 肿瘤最新文章合集

• •

2 型糖尿病的恶性肿瘤风险:一项基于人群的前瞻性研究

陈伦文, 周阳, 闫国栋, 沈怡, 孙晨, 蔡婉丽, 褚敏捷, 肖静   

  1. 226019 江苏省南通市,南通大学公共卫生学院
  • 基金资助:
    国家自然科学基金资助项目( 82273715)——选择性多聚腺苷酸化关联的遗传变异对肺腺癌发病风险的影响及机制
    研究

CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing   

  1. School of Public HealthNantong UniversityNantongJiangsu 226019China

摘要: 背景 近年来,随着人口老龄化和生活方式的改变,2 型糖尿病(T2DM)患者恶性肿瘤高发,且T2DM 病程和糖尿病治疗药物的使用可能加速恶性肿瘤的发生。目的 分析 T2DM 患者恶性肿瘤的发生风险及影响因素。方法 前瞻性纳入 2011-10-01 至 2020-12-31 在南通大学附属医院首次治疗或确诊的 T2DM 患者,随访终止日期为 2021-09-30。通过身份证信息与南通市肿瘤登记系统和死因登记系统联动匹配,获得患者的肿瘤发生与全死因信息。按性别分别计算 T2DM 患者中恶性肿瘤的发病率和标化发病率比(SIR)。采用 Cox 比例风险回归分析探讨 T2DM病程和药物的使用对 T2DM 患者发生恶性肿瘤的影响。结果 本研究共纳入 T2DM 患者 12 006 例,其中男 6 328 例(52.71%)、女 5 678 例(47.29%);经过 56 371 人年的观察(男性 29 543 人年,女性 26 824 人年),共观察到合并恶性肿瘤组 601 例和单纯 T2DM 组 11 405 例。T2DM 患者恶性肿瘤发病率男性 1 093.24/10 万,女性 1 032.51/10 万。男性 T2DM 患者发生结直肠癌( SIR=2.03)、前列腺癌( SIR=2.24)、胰腺癌( SIR=1.75)、肾癌( SIR=4.25)、甲状腺癌( SIR=3.50)的发生率高于一般人群,而发生肺癌( SIR=0.61)、食道癌( SIR=0.22)的发生率低于一般人群;女性 T2DM 患者发生乳腺癌( SIR=2.59)、结直肠癌( SIR=1.57)、胰腺癌( SIR=2.10)、子宫内膜癌( SIR=2.83)、肾癌( SIR=3.67)、甲状腺癌( SIR=4.00)的发生率高于一般人群,而发生食道癌( SIR=0.27)的发生率低于一般人群。与病程 1~<3 年的患者相比,男性 T2DM 病程 <1 年、5~<10 年、≥ 10 年分别增加 91%〔 HR=1.91, 95%CI(1.15,3.20)〕、123%〔 HR=2.23, 95%CI(1.37,3.64)〕和 71%〔 HR=1.71, 95%CI(1.04,2.80)〕的恶性肿瘤发生风险;女性病程5~<10 年、≥ 10 年分别增加 79%〔 HR=1.79, 95%CI(1.10,2.92)〕、99%〔 HR=1.99, 95%CI(1.24,3.19)〕的恶性肿瘤发生风险。单独使用胰岛素能分别增加男、女性 72%〔 HR=1.72, 95%CI(1.25,2.36)〕和 116%〔 HR=2.16,95%CI(1.53,3.05)〕恶性肿瘤发生风险,且男性胰岛素使用与病程两者存在交互作用,随着病程的逐年增加平均减缓 6% 的男性 T2DM 患者发生恶性肿瘤的风险( P 交互 =0.006) 。结论 除食道癌和男性肺癌外,T2DM 患者结直肠癌、前列腺癌、胰腺癌、肾癌、甲状腺癌、乳腺癌、子宫内膜癌的发生风险增加 57%~300%,且与病程和使用胰岛素有关,男性 T2DM 病程 5~<10 年,女性 T2DM 病程≥ 10 年的患者发生恶性肿瘤的风险最大,但胰岛素的使用和 T2DM 病程的增加对并发恶性肿瘤有拮抗的交互作用。

关键词:

癌;队列研究;糖尿病, 2 型;Cox 比例风险回归;2 型糖尿病病程

Abstract:

Background In recent yearswith the aging of the population and the change of lifestylespatients with type 2 diabetes mellitus T2DMhave a high prevalence of malignanciesthe duration of T2DM and the use of T2DM drugs may accelerate the occurrence of malignant tumor. Objective To analyze the risk of incidence and influencing factors of malignant tumors in patients with T2DM. Methods Patients with T2DM who were first treated or diagnosed at the Affiliated Hospital of Nantong University from October 12011 to December 312020 were prospectively includedwith the follow-up termination date of September 302021. The information of tumor incidence and full cause of death of patients were obtained by matching the ID information with the linkage records of the chronic disease tumor registration system and the cause of death registration system of Nantong City. The incidence rate and standardized incidence ratioSIRof malignant tumors among T2DM patients were calculated separately by gender. Cox proportional hazard regression model was used to explore the effects of the duration of T2DM and drug use on the incidence of malignant tumor in T2DM patients. Results A total of 12 006 patients with T2DM were included in this studyinvolving 6 328 males 52.71%and 5 678 females 47.29%. After 56 371 personyears of observation29 543 person-years for males and 26 824 person-years for females),601 patients with malignant tumor and 11 405 patients with T2DM alone were observed. The incidence of malignant tumor in T2DM patients was 1 093.24/100 000 in men and 1 032.51/100 000 in womenrespectively. The incidences of colorectal cancerSIR=2.03),prostate cancer SIR=2.24), pancreatic cancerSIR=1.75),kidney cancerSIR=4.25),thyroid cancer SIR=3.50were higher in male T2DM patients

than general populationwhile the incidences of lung cancer SIR=0.61and esophageal cancer SIR=0.22were lower than general population. The incidences of breast cancer SIR=2.59),colorectal cancer SIR=1.57),pancreatic cancer  SIR=2.10),endometrial cancer SIR=2.83),kidney cancerSIR=3.67),thyroid cancerSIR=4.00were higher in

female T2DM patients than general populationwhile the incidence of esophageal cancerSIR=0.27was lower than general population. Compared with T2DM patients with disease duration of 1 to <3 yearsthe risk of malignant tumor was increased by 91% HR=1.9195%CI1.153.20)〕,123%HR=2.2395%CI1.373.64)〕 and 71%HR=1.7195%CI1.042.80)〕in male with disease duration <1 year5 to <10 years and 10 yearsrespectivelythe risk of malignant tumor was increased by 79%HR=1.7995%CI1.102.92)〕 and 99%HR=1.9995%CI1.243.19)〕 in female with T2DM duration of 5 to <10 years and 10 yearsrespectively. Insulin use alone increased the risk of malignant tumor by 72%HR=1.7295%CI1.252.36)〕and 116%HR=2.1695%CI1.533.05)〕 in male and femalerespectively. In additionthere was a significant interaction between insulin use and the duration of T2DM in malethe risk of malignant tumor was decreased by an average of 6% with the interaction over the yearsP=0.006. Conclusion In addition to esophageal cancer in both sexes and lung cancer in malethe risk of colorectal cancerprostate cancerpancreatic cancerkidney cancerthyroid cancerbreast cancer and endometrial cancer increase by 57%-300% in patients with T2DMand associated with the disease duration and insulin usewith the greatest risk of malignant tumor in male with disease duration of 5 to <10 years and in female with disease duration of 10 years. Howeverthere is an antagonistic interaction between insulin use and increased duration of T2DM disease on the incidence of malignant tumor.

Key words:

CarcinomaCohort studiesDiabetes mellitus, type 2Cox proportional hazard regressionDuration of T2DM